U.S. FDA Grants Priority Review for Pfizer’s New Drug Application for Glasdegib in Patients with Previously Untreated Acute Myeloid Leukemia Pharmaceutical Investing
LYNPARZA (olaparib) Significantly Delays Disease Progression in Phase 3 First-Line SOLO-1 Trial for Ovarian Cancer Pharmaceutical Investing
Galectin Therapeutics Receives Patent for GR-MD-02 Patent for Method and Treatment of Pulmonary Fibrosis Pharmaceutical Investing
GBT Announces Positive Top-line Data from Part A of the Phase 3 HOPE Study of Voxelotor in Sickle Cell Disease Pharmaceutical Investing
Aquinox Announces Topline Results of Phase 3 LEADERSHIP 301 Clinical Trial in Interstitial Cystitis/Bladder Pain Syndrome Pharmaceutical Investing
Pain Therapeutics Announces Results of FDA Advisory Committee Meeting for REMOXY ER Pharmaceutical Investing
Aerpio Pharmaceuticals Announces Uplisting to Nasdaq Capital Market and Pricing of $45.0 Million Public Offering of Common Stock Pharmaceutical Investing
Arcus Biosciences and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Lead Programs in Triple-Combination Studies Biotech Investing
Agios and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Ivosidenib in Greater China Biotech Investing
ZEMDRITM (plazomicin) Approved by FDA for the Treatment of Adults with Complicated Urinary Tract Infections Pharmaceutical Investing
